Management of infections by the human polyomavirus JC: past, present and future

References

• Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1(7712), 1257–1260 (1971).
   PubMed Web of Science ®Google Scholar
• Gardner SD, Field AM, Coleman DV, Hulme B. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1(7712), 1253–1257 (1971).
   PubMed Web of Science ®Google Scholar
• Regenmortel MHV, Fauquet CM, Bishop DHL et al. Virus Taxonomy: The Seventh Report of the International Committee on Taxonomy of Viruses. Academic Press, San Diego, USA (2000).
   Google Scholar
• Frisque RJ, Bream GL, Cannella MT. Human polyomavirus JC virus genome. J. Virol. 51(2), 458–469 (1984).
   PubMed Web of Science ®Google Scholar
• Okada Y, Endo S, Takahashi H et al. Distribution and function of JCV agnoprotein. J. Neurovirol. 7(4), 302–306 (2001).
   PubMedGoogle Scholar
• Amemiya K, Traub R, Durham L, Major EO. Interaction of a nuclear factor-1-like protein with the regulatory region of the human polyomavirus JC virus. J. Biol. Chem. 264(12), 7025–7032 (1989).
   PubMedGoogle Scholar
• Chang CF, Gallia GL, Muralidharan V et al. Evidence that replication of human neurotropic JC virus DNA in glial cells is regulated by the sequence-specific single-stranded DNA-binding protein Pur α. J. Virol. 70(6), 4150–4156 (1996).
   PubMedGoogle Scholar
• Ault GS. Activity of JC virus archetype and PML-type regulatory regions in glial cells. J. Gen. Virol. 78(Pt. 1), 163–169 (1997).
   PubMedGoogle Scholar
• Jensen PN, Major EO. A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region. J. Neurovirol. 7(4), 280–287 (2001).
   PubMed Web of Science ®Google Scholar
• Richardson EP Jr. Progressive multifocal leukoencephalopathy. N. Engl. J. Med. 265, 815–823 (1961).
   PubMed Web of Science ®Google Scholar
• Astrom KE, Mancall EL, Richardson EP. Progressive multifocal leukoencephalopathy. Brain 81, 93–127 (1958).
   PubMed Web of Science ®Google Scholar
• Major EO, Amemiya K, Tornatore CS, Houff SA, Berger JR. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin. Microbiol. Rev. 5(1), 49–73 (1992).
   PubMed Web of Science ®Google Scholar
• Berger JR. Progressive multifocal leukoencephalopathy. Curr. Treat. Options Neurol. 2(4), 361–368 (2000).
   PubMedGoogle Scholar
• Astrom KE, Stoner GL. Early pathological changes in progressive multifocal leukoencephalopathy: a report of two asymptomatic cases occurring prior to the AIDS epidemic. Acta Neuropathol. (Berl). 88(1), 93–105 (1994).
   PubMedGoogle Scholar
• Dang-Tan T, Mahmud SM, Puntoni R, Franco EL. Polio vaccines, simian virus 40, and human cancer: the epidemiologic evidence for a causal association. Oncogene 23(38), 6535–6540 (2004).
   Google Scholar
• Reiss K, Khalili K. Viruses and cancer: lessons from the human polyomavirus, JCV. Oncogene 22(42), 6517–6523 (2003).
   PubMedGoogle Scholar
• Lopez-Rios F, Illei PB, Rusch V, Ladanyi M. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 364(9440), 1157–1166 (2004).
   PubMed Web of Science ®Google Scholar
• Mayall F, Barratt K, Shanks J. The detection of simian virus 40 in mesotheliomas from New Zealand and England using real time FRET probe PCR protocols. J. Clin. Pathol. 56(10), 728–730 (2003).
   PubMed Web of Science ®Google Scholar
• Rollison DE, Utaipat U, Ryschkewitsch C et al. Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories. Int. J. Cancer 113(5), 769–774 (2005).
   PubMed Web of Science ®Google Scholar
• Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl. Int. 17(11), 658–665 (2004).
   Google Scholar
• Osorio S, de la Camara R, Golbano N et al. Progressive multifocal leukoencephalopathy after stem cell transplantation, unsuccessfully treated with cidofovir. Bone Marrow Transplant. 30(12), 963–966 (2002).
   PubMed Web of Science ®Google Scholar
• Kazory AM, Ducloux D. Polyomaviruses and transplant patients: new concepts. Transpl. Infect. Dis. 6(3), 136–137 (2004).
   PubMedGoogle Scholar
• Herman J, Van Ranst M, Snoeck R et al. Polyomavirus infection in pediatric renal transplant recipients: evaluation using a quantitative real-time PCR technique. Pediatr. Transplant. 8(5), 485–492 (2004).
   PubMed Web of Science ®Google Scholar
• Randhawa P, Baksh F, Aoki N, Tschirhart D, Finkelstein S. JC virus infection in allograft kidneys: analysis by polymerase chain reaction and immunohistochemistry. Transplantation 71(9), 1300–1303 (2001).
   PubMedGoogle Scholar
• Baksh FK, Finkelstein SD, Swalsky PA et al. Molecular genotyping of BK and JC viruses in human polyomavirus-associated interstitial nephritis after renal transplantation. Am. J. Kidney Dis. 38(2), 354–365 (2001).
   PubMedGoogle Scholar
• Wen MC, Wang CL, Wang M et al. Association of JC virus with tubulointerstitial nephritis in a renal allograft recipient. J. Med. Virol. 72(4), 675–678 (2004).
   PubMed Web of Science ®Google Scholar
• Brown P, Tsai T, Gajdusek DC. Seroepidemiology of human papovaviruses. Discovery of virgin populations and some unusual patterns of antibody prevalence among remote peoples of the world. Am. J. Epidemiol. 102(4), 331–340 (1975).
   PubMed Web of Science ®Google Scholar
• Monaco MC, Atwood WJ, Gravell M, Tornatore CS, Major EO. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J. Virol. 70(10), 7004–7012 (1996).
   PubMed Web of Science ®Google Scholar
• Houff SA, Major EO, Katz DA et al. Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N. Engl. J. Med. 318(5), 301–305 (1988).
   PubMed Web of Science ®Google Scholar
• Jensen PN, Major EO. Viral variant nucleotide sequences help expose leukocytic positioning in the JC virus pathway to the CNS. J. Leukoc. Biol. 65(4), 428–438 (1999).
   PubMedGoogle Scholar
• Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J. Infect. Dis. 186(Suppl. 2), S180–S186 (2002).
   PubMed Web of Science ®Google Scholar
• Seth P, Diaz F, Major EO. Advances in the biology of JC virus and induction of progressive multifocal leukoencephalopathy. J. Neurovirol. 9(2), 236–246 (2003).
   PubMed Web of Science ®Google Scholar
• Aksamit AJ Jr. Progressive multifocal leukoencephalopathy: a review of the pathology and pathogenesis. Microsc. Res. Tech. 32(4), 302–311 (1995).
   PubMedGoogle Scholar
• Messam CA, Hou J, Gronostajski RM, Major EO. Lineage pathway of human brain progenitor cells identified by JC virus susceptibility. Ann. Neurol. 53(5), 636–646 (2003).
   PubMed Web of Science ®Google Scholar
• Laghi L, Randolph AE, Chauhan DP et al. JC virus DNA is present in the mucosa of the human colon and in colorectal cancers. Proc. Natl Acad. Sci. USA 96(13), 7484–7489 (1999).
   PubMed Web of Science ®Google Scholar
• Kitamura T, Yogo Y, Kunitake T et al. Effect of immunosuppression on the urinary excretion of BK and JC polyomaviruses in renal allograft recipients. Int. J. Urol. 1(1), 28–32 (1994).
   PubMedGoogle Scholar
• Behzad-Behbahani A, Klapper PE, Vallely PJ, Cleator GM, Khoo SH. Detection of BK virus and JC virus DNA in urine samples from immunocompromised (HIV-infected) and immunocompetent (HIV-non-infected) patients using polymerase chain reaction and microplate hybridisation. J. Clin.Virol. 29(4), 224–229 (2004).
   PubMed Web of Science ®Google Scholar
• Bofill-Mas S, Pina S, Girones R. Documenting the epidemiologic patterns of polyomaviruses in human populations by studying their presence in urban sewage. Appl. Environ. Microbiol. 66(1), 238–245 (2000).
   PubMed Web of Science ®Google Scholar
• Houff SA, Katz D, Kufta CV, Major EO. A rapid method for in situ hybridization for viral DNA in brain biopsies from patients with AIDS. AIDS 3(12), 843–845 (1989).
   PubMed Web of Science ®Google Scholar
• Knoll A, Stoehr R, Jilg W, Hartmann A. Low frequency of human polyomavirus BKV and JCV DNA in urothelial carcinomas of the renal pelvis and renal cell carcinomas. Oncol. Rep. 10(2), 487–491 (2003).
   PubMedGoogle Scholar
• Taoufik Y, Gasnault J, Karaterki A et al. Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J. Infect. Dis. 178(6), 1816–1820 (1998).
   PubMed Web of Science ®Google Scholar
• Ryschkewitsch C, Jensen P, Hou J et al. Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J. Virol. Methods 121(2), 217–221 (2004).
   PubMed Web of Science ®Google Scholar
• Yiannoutsos CT, Major EO, Curfman B et al. Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Ann. Neurol. 45(6), 816–821 (1999).
   PubMed Web of Science ®Google Scholar
• Koralnik IJ, Boden D, Mai VX, Lord CI, Letvin NL. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 52(2), 253–260 (1999).
   PubMed Web of Science ®Google Scholar
• Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J. Neurovirol. 9(Suppl. 1), 88–92 (2003).
   PubMed Web of Science ®Google Scholar
• Aoki N, Kitamura T, Tominaga T et al. Immunohistochemical detection of JC virus in nontumorous renal tissue of a patient with renal cancer but without progressive multifocal leukoencephalopathy. J. Clin. Microbiol. 37(4), 1165–1167 (1999).
   PubMedGoogle Scholar
• Johnson SA. Nucleoside analogues in the treatment of haematological malignancies. Exp. Opin. Pharmacother. 2(6), 929–943 (2001).
   PubMedGoogle Scholar
• O'Riordan T, Daly PA, Hutchinson M, Shattock AG, Gardner SD. Progressive multifocal leukoencephalopathy-remission with cytarabine. J. Infect. 20(1), 51–54 (1990).
   PubMed Web of Science ®Google Scholar
• Bauer WR, Turel AP Jr, Johnson KP. Progressive multifocal leukoencephalopathy and cytarabine. Remission with treatment. J. Am. Med. Assoc. 226(2), 174–176 (1973).
   Google Scholar
• Marriott PJ, O'Brien MD, Mackenzie IC, Janota I. Progressive multifocal leucoencephalopathy: remission with cytarabine. J. Neurol. Neurosurg. Psychiatry 38(3), 205–209 (1975).
   PubMedGoogle Scholar
• Garrels K, Kucharczyk W, Wortzman G, Shandling M. Progressive multifocal leukoencephalopathy: clinical and MR response to treatment. Am. J. Neuroradiol. 17(3), 597–600 (1996).
   PubMedGoogle Scholar
• Guarino M, D'Alessandro R, Rinaldi R et al. Progressive multifocal leucoencephalopathy in AIDS: treatment with cytosine arabinoside. AIDS 9(7), 819–820 (1995).
   PubMedGoogle Scholar
• Portegies P, Algra PR, Hollak CE et al. Response to cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet 337(8742), 680–681 (1991).
   Google Scholar
• Moreno S, Miralles P, Diaz MD et al. Cytarabine therapy for progressive multifocal leukoencephalopathy in patients with AIDS. Clin. Infect. Dis. 23(5), 1066–1068 (1996).
   PubMed Web of Science ®Google Scholar
• Hall CD, Dafni U, Simpson D et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N. Engl. J. Med. 338(19), 1345–1351 (1998).
   PubMed Web of Science ®Google Scholar
• De Luca A, Giancola ML, Cingolani A et al. Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy. Clin. Infect. Dis. 28(3), 624–628 (1999).
   PubMed Web of Science ®Google Scholar
• Groothuis DR, Levy RM. The entry of antiviral and antiretroviral drugs into the central nervous system. J. Neurovirol. 3(6), 387–400 (1997).
   PubMed Web of Science ®Google Scholar
• Levy RM, Ward S, Schalgeter K, Groothuis D. Alternative delivery systems for antiviral nucleosides and antisense oligonucleotides to the brain. J. Neurovirol. 3(Suppl. 1), S74–S75 (1997).
   Google Scholar
• Groothuis DR, Benalcazar H, Allen CV et al. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration. Brain Res. 856(1–2), 281–290 (2000).
   PubMed Web of Science ®Google Scholar
• Levy RM, Major E, Ali MJ, Cohen B, Groothius D. Convection-enhanced intraparenchymal delivery (CEID) of cytosine arabinoside (AraC) for the treatment of HIV-related progressive multifocal leukoencephalopathy (PML). J. Neurovirol. 7(4), 382–385 (2001).
   PubMed Web of Science ®Google Scholar
• Aksamit A. Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside. J. Neurovirol. 7(4), 386–390 (2001).
   PubMed Web of Science ®Google Scholar
• Hou J, Major EO. The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J. Neurovirol. 4(4), 451–456 (1998).
   PubMed Web of Science ®Google Scholar
• Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol Res. 10(10), 523–531 (1998).
   PubMedGoogle Scholar
• De Clercq E. Therapeutic potential of phosphonylmethoxyalkylpurines and -pyrimidines as antiviral agents. Drugs Exp. Clin. Res. 16(7), 319–326 (1990).
   PubMedGoogle Scholar
• Rahhal FM. Treatment advances for CMV retinitis. AIDS Read. 9(1)28, 31–34 (1999).
   Google Scholar
• Andrei G, Snoeck R, Vandeputte M, De Clercq E. Activities of various compounds against murine and primate polyomaviruses. Antimicrob. Agents Chemother. 41(3), 587–593 (1997).
   PubMed Web of Science ®Google Scholar
• Sadler M, Chinn R, Healy J et al. New treatments for progressive multifocal leukoencephalopathy in HIV-1-infected patients. AIDS 12(5), 533–535 (1998).
   PubMedGoogle Scholar
• Blick G, Whiteside M, Griegor P et al. Successful resolution of progressive multifocal leukoencephalopathy after combination therapy with cidofovir and cytosine arabinoside. Clin. Infect. Dis. 26(1), 191–192 (1998).
   PubMed Web of Science ®Google Scholar
• Portilla J, Boix V, Roman F, Reus S, Merino E. Progressive multifocal leukoencephalopathy treated with cidofovir in HIV-infected patients receiving highly active anti-retroviral therapy. J. Infect. 41(2), 182–184 (2000).
   PubMed Web of Science ®Google Scholar
• Tubridy N, Wells C, Lewis D, Schon F. Unsuccessful treatment with cidofovir and cytarabine in progressive multifocal leukoencephalopathy associated with dermatomyositis. J. R. Soc. Med. 93(7), 374–375 (2000).
   PubMedGoogle Scholar
• Houston S, Roberts N, Mashinter L. Failure of cidofovir therapy in progressive multifocal leukoencephalopathy unrelated to human immunodeficiency virus. Clin. Infect. Dis. 32(1), 150–152 (2001).
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Schwarzler F, Beck R et al. Progressive multifocal leukoencephalopathy: cidofovir therapy in three patients with underlying hematological disease. J. Neurol. 250(5), 612–614 (2003).
   PubMedGoogle Scholar
• De Luca A, Giancola ML, Ammassari A et al. Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. AIDS 14(14), F117–F121 (2000).
   PubMed Web of Science ®Google Scholar
• De Luca A, Giancola ML, Ammassari A et al. Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study. J. Neurovirol. 7(4), 364–368 (2001).
   PubMed Web of Science ®Google Scholar
• Gasnault J, Kousignian P, Kahraman M et al. Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring. J. Neurovirol. 7(4), 375–381 (2001).
   PubMed Web of Science ®Google Scholar
• Marra CM, Rajicic N, Barker DE et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. Aids 16(13), 1791–1797 (2002).
   PubMed Web of Science ®Google Scholar
• Conway B, Halliday WC, Brunham RC. Human immunodeficiency virus-associated progressive multifocal leukoencephalopathy: apparent response to 3'-azido-3'-deoxythymidine. Rev. Infect. Dis. 12(3), 479–482 (1990).
   PubMedGoogle Scholar
• Singer EJ, Stoner GL, Singer P et al. AIDS presenting as progressive multifocal leukoencephalopathy with clinical response to zidovudine. Acta Neurol. Scand. 90(6), 443–447 (1994).
   PubMed Web of Science ®Google Scholar
• Power C, Nath A, Aoki FY, Bigio MD. Remission of progressive multifocal leukoencephalopathy following splenectomy and antiretroviral therapy in a patient with HIV infection. N. Engl. J. Med. 336(9), 661–662 (1997).
   PubMed Web of Science ®Google Scholar
• Elliot B, Aromin I, Gold R, Flanigan T, Mileno M. 2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy. Lancet 349(9055), 850 (1997).
   PubMedGoogle Scholar
• Domingo P, Guardiola JM, Iranzo A, Margall N. Remission of progressive multifocal leucoencephalopathy after antiretroviral therapy. Lancet 349(9064), 1554–1555 (1997).
   PubMedGoogle Scholar
• Inui K, Miyagawa H, Sashihara J et al. Remission of progressive multifocal leukoencephalopathy following highly active antiretroviral therapy in a patient with HIV infection. Brain Dev. 21(6), 416–419 (1999).
   PubMedGoogle Scholar
• Tassie JM, Gasnault J, Bentata M et al. Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV. AIDS 13(14), 1881–1887 (1999).
   PubMed Web of Science ®Google Scholar
• De Luca A, Giancola ML, Ammassari A et al. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J. Infect. Dis. 182(4), 1077–1083 (2000).
   PubMed Web of Science ®Google Scholar
• Giudici B, Vaz B, Bossolasco S et al. Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin. Infect. Dis. 30(1), 95–99 (2000).
   PubMed Web of Science ®Google Scholar
• Miralles P, Berenguer J, Garcia de Viedma D et al. Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy. AIDS 12(18), 2467–2472 (1998).
   PubMed Web of Science ®Google Scholar
• Gasnault J, Taoufik Y, Goujard C et al. Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy. J. Neurovirol. 5(4), 421–429 (1999).
   PubMed Web of Science ®Google Scholar
• Clifford DB, Yiannoutsos C, Glicksman M et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52(3), 623–625 (1999).
   PubMed Web of Science ®Google Scholar
• Antinori A, Cingolani A, Lorenzini P et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J. Neurovirol. 9(Suppl. 1), 47–53 (2003).
   PubMed Web of Science ®Google Scholar
• Tantisiriwat W, Tebas P, Clifford DB, Powderly WG, Fichtenbaum CJ. Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin. Infect. Dis. 28(5), 1152–1154 (1999).
   PubMedGoogle Scholar
• Albrecht H, Hoffmann C, Degen O et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 12(10), 1149–1154 (1998).
   PubMed Web of Science ®Google Scholar
• Taoufik Y, Delfraissy JF, Gasnault J. Highly active antiretroviral therapy does not improve survival of patients with high JC virus load in the cerebrospinal fluid at progressive multifocal leukoencephalopathy diagnosis. AIDS 14(6), 758–759 (2000).
   PubMed Web of Science ®Google Scholar
• Miralles P, Berenguer J, Lacruz C et al. Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. AIDS 15(14), 1900–1902 (2001).
   PubMed Web of Science ®Google Scholar
• Safdar A, Rubocki RJ, Horvath JA, Narayan KK, Waldron RL. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin. Infect. Dis. 35(10), 1250–1257 (2002).
   PubMed Web of Science ®Google Scholar
• Di Giambenedetto S, Vago G, Pompucci A et al. Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity? Neurology 63(12), 2452–2453 (2004).
   PubMed Web of Science ®Google Scholar
• Cheng VC, Yuen KY, Chan WM et al. Immunorestitution disease involving the innate and adaptive response. Clin. Infect. Dis. 30(6), 882–892 (2000).
   PubMed Web of Science ®Google Scholar
• Cinque P, Pierotti C, Vigano MG et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J. Neurovirol. 7(4), 358–363 (2001).
   PubMed Web of Science ®Google Scholar
• Berger JR, Levy RM, Flomenhoft D, Dobbs M. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 44(3), 341–349 (1998).
   PubMed Web of Science ®Google Scholar
• Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J. Neurovirol. 9(Suppl. 1), 25–31 (2003).
   PubMed Web of Science ®Google Scholar
• Du Pasquier RA, Kuroda MJ, Schmitz JE et al. Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy. J. Virol. 77(22), 11918–11926 (2003).
   PubMed Web of Science ®Google Scholar
• Gasnault J, Kahraman M, de Goer de Herve MG et al. Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS 17(10), 1443–1449 (2003).
   PubMed Web of Science ®Google Scholar
• Arun B, Frenkel EP. Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues. Exp. Opin. Pharmacother. 2(3), 491–505 (2001).
   PubMedGoogle Scholar
• Kerr DA, Chang CF, Gordon J, Bjornsti MA, Khalili K. Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin. Virology 196(2), 612–618 (1993).
   PubMed Web of Science ®Google Scholar
• Vollmer-Haase J, Young P, Ringelstein EB. Efficacy of camptothecin in progressive multifocal leucoencephalopathy. Lancet 349(9062), 1366 (1997).
   PubMedGoogle Scholar
• Royal W, 3rd, Dupont B, McGuire D et al. Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J. Neurovirol. 9(3), 411–419 (2003).
   PubMed Web of Science ®Google Scholar
• Colosimo C, Lebon P, Martelli M, Tumminelli F, Mandelli F. α-interferon therapy in a case of probable progressive multifocal leukoencephalopathy. Acta Neurol. Belg. 92(1), 24–29 (1992).
   PubMed Web of Science ®Google Scholar
• Tashiro K, Doi S, Moriwaka F, Maruo Y, Nomura M. Progressive multifocal leucoencephalopathy with magnetic resonance imaging verification and therapeutic trials with interferon. J. Neurol. 234(6), 427–429 (1987).
   PubMed Web of Science ®Google Scholar
• Huang SS, Skolasky RL, Dal Pan GJ, Royal W III, McArthur JC. Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study. J. Neurovirol. 4(3), 324–332 (1998).
   PubMed Web of Science ®Google Scholar
• Geschwind MD, Skolasky RI, Royal WS, McArthur JC. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J. Neurovirol. 7(4), 353–357 (2001).
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Jaeckle KA, Birdwell RR et al. Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2. Bone Marrow Transplant. 20(11), 983–987 (1997).
   PubMed Web of Science ®Google Scholar
• Baum S, Ashok A, Gee G et al. Early events in the life cycle of JC virus as potential therapeutic targets for the treatment of progressive multifocal leukoencephalopathy. J. Neurovirol. 9(Suppl. 1), 32–37 (2003).
   PubMedGoogle Scholar
• Atwood WJ. A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: implications for prophylactic and therapeutic treatment of progressive multifocal leukencephalopathy. J. Neurovirol. 7(4), 307–310 (2001).
   PubMed Web of Science ®Google Scholar
• Elphick GF, Querbes W, Jordan JA et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306(5700), 1380–1383 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia De Viedma D, Diaz Infantes M, Miralles P et al. JC virus load in progressive multifocal leukoencephalopathy: analysis of the correlation between the viral burden in cerebrospinal fluid, patient survival, and the volume of neurological lesions. Clin. Infect. Dis. 34(12), 1568–1575 (2002).
   PubMedGoogle Scholar
• Du Pasquier RA, Kuroda MJ, Zheng Y et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 127(Pt 9), 1970–1978 (2004).
   PubMed Web of Science ®Google Scholar